Doctors should discuss financial concerns of cancer patients (DukeHealth.org)
May 16, 2013
Most cancer patients would like to talk about the cost of their care with their doctors, but often don't because they fear the discussion could compromise the quality of their treatment, researchers at Duke Cancer Institute report.
Duke researchers describe how breast cancer cells acquire drug resistance (DukeHealth.org)
May 7, 2013
A seven-year quest to understand how breast cancer cells resist treatment with the targeted therapy lapatinib has revealed a previously unknown molecular network that regulates cell death. The discovery provides new avenues to overcome drug resistance, according to researchers at Duke Cancer Institute.
Immortality gene mutation identifies brain tumors and other cancers (DukeHealth.org)
Mar. 18, 2013
Newly identified mutations in a gene that makes cells immortal appear to play a pivotal role in three of the most common types of brain tumors, as well as cancers of the liver, tongue and urinary tract, according to research led by Duke Cancer Institute.
Sickle Cells Show Potential to Attack Aggressive Cancer Tumors (DukeHealth.org)
Jan. 9, 2013
By harnessing the very qualities that make sickle cell disease a lethal blood disorder, a research team led by Duke Medicine and Jenomic, a private cancer research company in Carmel, Calif., has developed a way to deploy the misshapen red blood cells to fight cancer tumors.
New Breast Cancer Drug Halts Tumor Growth Better Than Standard Therapy (DukeHealth.org)
June 4, 2012
A new cancer treatment that links chemotherapy with an agent that homes in on specific breast cancer cells was significantly better than the current drug regimen at keeping patients' advanced tumors from progressing, according to results from a Phase III clinical trial led by Kimberly Blackwell, M.D., of the Duke Cancer Institute.
Cholesterol-lowering drugs may slow benign prostate growth (DukeHealth.org)
May 21, 2012
Statins drugs prescribed to treat high cholesterol may also work to slow benign prostate growth in men who have elevated PSA levels, according to an analysis led by researchers at Duke University Medical Center.